Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

Inclusion Criteria

• •1. Are inadequately controlled with single or multiple OHA as evidenced by an HbA1c \> 7.0%
• •2. Have presented during the routine course of care and, together with their physician, have decided to initiate treatment with either exenatide twice daily or conventional insulin therapy with basal insulin (insulin glargine, detemir, protaminated insulin lispro, protaminated human insulin) added to the existing treatment with OHA
• •3. Have not been treated with GLP-1 receptor agonist for more than 7 consecutive days within 3 months before entering the study
• •4. Have not been treated with insulins for more than 7 consecutive days within last 3 months or more than 3 months in the course of the disease
• •5. Are not simultaneously participating in another study which includes an investigational drug or procedure at study entry
• •6. Have been fully informed and given their written consent for use of their data